Peptides DB

Research-centric peptide and protocol reference hub

ARA 290 vs PE 22-28

Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team

ARA 290: Research use — not FDA-approvedPE 22-28: Research use — not FDA-approved

A data-driven comparison of ARA 290 and PE 22-28 (also searched as PE 22-28 vs ARA 290) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

ARA 290 centers on neuro, while PE 22-28 leans toward metabolic. On indexed research, PE 22-28 is ahead (ARA 290: 4 studies, Preclinical; PE 22-28: 5, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • ARA 290 is strongest for neuro; PE 22-28 for metabolic.
  • Evidence: ARA 290 Preclinical (4 studies) vs PE 22-28 Human evidence (5).
  • Both are research-use compounds — not FDA-approved.

Effect profiles, overlaid

HealingMuscleMetabolicNeuroSleepInflammationSkin
ARA 290PE 22-28

At a glance

ARA 290Preclinical

Tissue-Protective Peptide | Innate Repair Receptor Agonist

Strongest: NeuroStudies: 4Level: Extensively Studied
PE 22-28Human evidence

TREK-1 Channel Blocker | Shortened Spadin Analog

Strongest: MetabolicStudies: 5Level: Emerging

ARA 290 vs PE 22-28: side-by-side

MetricARA 290PE 22-28
ClassHealingCognitive
Regulatory statusResearch use onlyResearch use only
Evidence gradePreclinicalHuman evidence
Studies indexed45
Research levelExtensively StudiedEmerging
Strongest effectNeuro & moodMetabolic & appetite
Healing & recovery2.32.0
Muscle & body comp2.20.0
Metabolic & appetite1.74.0
Neuro & mood3.03.0
Sleep & circadian1.00.0
Inflammation & immune2.72.0
Skin & aesthetics2.20.0

▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).

What is PE 22-28?

### Summary PE 22-28 is a peptide that has garnered attention in various research contexts, particularly in relation to vascular health and metabolic conditions. Its potential implications in gestational diabetes and placental function are areas of ongoing investigation.

Full PE 22-28 profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingARA 2902.3/5 effect signal
MuscleARA 2902.2/5 effect signal
MetabolicPE 22-284.0/5 effect signal
NeuroEvenBoth ~3.0/5
SleepARA 2901.0/5 effect signal
InflammationARA 2902.7/5 effect signal
SkinARA 2902.2/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack ARA 290 and PE 22-28?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

ARA 290 vs PE 22-28: side effects

ARA 290

No community-reported effects logged yet.

PE 22-28

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

ARA 290 has 4 approved studies indexed (Preclinical), and PE 22-28 has 5 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is ARA 290 or PE 22-28 better?

It depends on your goal. ARA 290 is strongest for neuro; PE 22-28 for metabolic. PE 22-28 has more indexed studies (5). See the goal-by-goal breakdown above.

Is ARA 290 or PE 22-28 better for weight loss?

PE 22-28 shows the stronger metabolic & appetite profile (4.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.

Is ARA 290 or PE 22-28 better for muscle?

ARA 290 leads on the muscle & body-composition axis (2.2/5).

Which has more research, ARA 290 or PE 22-28?

ARA 290 has 4 approved studies indexed (Preclinical); PE 22-28 has 5 (Human evidence). Higher counts mean more to read, not proven superiority.

Can you stack ARA 290 and PE 22-28?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of ARA 290 vs PE 22-28?

ARA 290: no community-reported effects logged yet. PE 22-28: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is ARA 290 or PE 22-28 FDA-approved?

ARA 290 is a research-use compound and is not FDA-approved. PE 22-28 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is PE 22-28 better than ARA 290?

For metabolic, PE 22-28 has the edge; for neuro, ARA 290 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

ARA 290 and PE 22-28 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.